ArticleCancers2024
SIR-EN-New Biomarker for Identifying Patients at Risk of Endometrial Carcinoma in Abnormal Uterine Bleeding at Menopause.
Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic value of contrast-enhanced ultrasound for the depth of myometrial infiltration in early endometrial cancer: a meta-analysis.Frontiers in oncology · 2025Pooled it
- Exploratory Analysis of Systemic Inflammatory Indices Across Locoregional Tumor Progression Parameters in Cervical Cancer: The CERTIFIKO Prospective Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Diagnostic performance of systemic inflammatory and nutritional indices and their association with clinicopathological features in endometrial cancer: a retrospective study.BMC women's health · 2026Observational
- Early Postoperative Albumin and Neutrophil Dynamics for Risk Stratification After Cytoreductive Surgery in Ovarian Cancer: A Retrospective Multicenter Cohort Study.Medicina (Kaunas, Lithuania) · 2026Observational
- A cross-validated deep learning framework for automated detection of DMBA-induced ovarian cancer from histopathological images with CA-125 biomarker support.Frontiers in artificial intelligence · 2026Article
- Development and validation of a blood biomarker risk prediction model for postmenopausal endometrioid endometrial cancer.Frontiers in endocrinology · 2026Article
- Additional Risk Factors Lead to a Measurable Inflammatory Response in Stage I Endometrial Cancer-A Prospective Multicentric Observational Study.Indian journal of surgical oncology · 2025Article
- When Should We Biopsy? A Risk Factor-Based Predictive Model for EIN and Endometrial Cancer.Cancers · 2025Article
- Inflammatory Indices vs. CA 125 for the Diagnosis of Early Ovarian Cancer: Evidence from a Multicenter Prospective Italian Cohort.Journal of personalized medicine · 2025Article
- Microsatellite Instability and Myometrial Infiltration in Low-Grade Endometrial Cancer: A Focus on MMR Heterodimer Dysfunction by a Retrospective Multicentric Italian Study.Journal of personalized medicine · 2025Article
- Article
- Article
- Inflammatory Indices and CA 125: A New Approach to Distinguish Ovarian Carcinoma and Borderline Tumors in Suspicious Ovarian Neoplasms from a Retrospective Observational Multicentric Study.Medicina (Kaunas, Lithuania) · 2025Observational
- Article
- Comprehensive Evaluation of Inflammatory Biomarkers in Cervical Cancer Treated with Chemoradiotherapy.Current oncology (Toronto, Ont.) · 2025Article
- Multiparametric MRI-based radiomics and deep learning for differentiating uterine serous carcinoma from endometrioid carcinoma: a multicenter retrospective study.Frontiers in oncology · 2025Article
- Clinical analysis of molecular typing of 146 cases of endometrial carcinoma.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the efficacy of a new biomarker, termed SIR-En, in identifying patients at risk of endometrial carcinoma among those presenting with abnormal uterine bleeding during menopause. MATERIAL AND
methodsA retrospective case-control analysis was conducted on 242 women with menopausal abnormal uterine bleeding and endometrial thickness ≥ 4 mm. Peripheral blood samples were collected within 7 days before histological diagnosis. systemic inflammatory reaction (SIR) indices were calculated, including NLR, MLR, PLR, and SII. SIR-En was derived by multiplying SII and endometrial thickness. Statistical analyses, including multivariate linear regression and ROC curve analysis, were performed to assess the diagnostic capability of SIR-En.
resultsPatients were categorized into endometrial hyperplasia (50 patients) and endometrial cancer (192 patients) groups. The SIR-En index was significantly higher in the carcinoma group (8710 vs. 6420;
conclusionsCombining systemic inflammatory indices with endometrial thickness, the SIR-En index can effectively distinguish between endometrial hyperplasia and carcinoma in menopausal women with abnormal uterine bleeding. Despite the retrospective design, the identified cutoff's high specificity and positive predictive value support its potential utility in clinical practice. Further prospective studies are required to validate these findings and optimize clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.